Nitorum Capital L.P. Has $56.25 Million Stake in MannKind Co. (NASDAQ:MNKD)

Nitorum Capital L.P. decreased its position in MannKind Co. (NASDAQ:MNKD - Free Report) by 4.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,747,316 shares of the biopharmaceutical company's stock after selling 410,191 shares during the quarter. MannKind makes up 6.5% of Nitorum Capital L.P.'s portfolio, making the stock its 4th biggest position. Nitorum Capital L.P. owned approximately 3.17% of MannKind worth $56,245,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of MannKind by 2.7% during the fourth quarter. Vanguard Group Inc. now owns 16,058,557 shares of the biopharmaceutical company's stock valued at $103,257,000 after acquiring an additional 420,334 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of MannKind by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 6,374,274 shares of the biopharmaceutical company's stock valued at $40,996,000 after acquiring an additional 35,346 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of MannKind by 275.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,887,609 shares of the biopharmaceutical company's stock valued at $31,427,000 after acquiring an additional 3,587,484 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in MannKind by 40.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,958,219 shares of the biopharmaceutical company's stock worth $19,022,000 after buying an additional 855,261 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in MannKind by 2.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,270,106 shares of the biopharmaceutical company's stock worth $14,597,000 after buying an additional 45,277 shares in the last quarter. Institutional investors own 49.55% of the company's stock.

MannKind Stock Down 0.2 %

NASDAQ:MNKD traded down $0.01 on Monday, hitting $4.73. The stock had a trading volume of 1,334,220 shares, compared to its average volume of 2,392,022. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of 67.57 and a beta of 1.22. The business's 50-day simple moving average is $4.99 and its two-hundred day simple moving average is $5.93. MannKind Co. has a 52-week low of $4.11 and a 52-week high of $7.63.

MannKind (NASDAQ:MNKD - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, meeting analysts' consensus estimates of $0.03. MannKind had a negative return on equity of 17.74% and a net margin of 8.07%. The firm had revenue of $76.78 million for the quarter, compared to analysts' expectations of $74.99 million. As a group, equities research analysts anticipate that MannKind Co. will post 0.1 EPS for the current year.

Analyst Ratings Changes

Several research firms recently commented on MNKD. Mizuho began coverage on MannKind in a report on Thursday, April 10th. They issued an "outperform" rating and a $12.00 price objective for the company. Wedbush reiterated an "outperform" rating and issued a $11.00 price objective on shares of MannKind in a report on Thursday, February 27th. Finally, StockNews.com upgraded MannKind from a "hold" rating to a "buy" rating in a report on Wednesday, March 19th. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, MannKind has a consensus rating of "Buy" and a consensus price target of $9.56.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.